Sagent, Qilu partner to commercialise complex injectable products in US
Sagent Pharmaceuticals and Qilu Pharmaceutical have announced a strategic collaboration to commercialise a portfolio of complex injectable products for the US market.
Sagent Pharmaceuticals and Qilu Pharmaceutical have announced a strategic collaboration to commercialise a portfolio of complex injectable products for the US market.
Lakeside Holding (Lakeside), through its subsidiary Sichuan Hupan Jincheng Enterprise Management, has entered into an equity transfer agreement for the acquisition of Hupan Pharmaceutical.
Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has secured a contract manufacturing deal valued at $1.24bn with an Asia-based pharmaceutical company.
ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.
German company Merck has introduced the first single-use reactor specifically designed for the production of antibody-drug conjugates (ADCs).
Novartis has announced the commencement of construction on two new radioligand therapy (RLT) manufacturing facilities in the US, in a bid to expand its production and supply chain capabilities in the sector.
RedHill Biopharma has launched Talicia in the UAE, a treatment option for adults with Helicobacter pylori (H. pylori) infection.
Merck has initiated commercial manufacturing of its first Good Manufacturing Practices (GMP)-compliant manufacturing line for cell culture media (CCM) in China.
Rosemont Pharmaceuticals, a developer of liquid medicines, has announced the acquisition of Pharma-Data, a research and development organisation based in Lavrion, Greece, enhancing its ability to develop products for worldwide market.
Amneal Pharmaceuticals has initiated the distribution of its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, to retail pharmacies across the US, including the State of California.